These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
525 related articles for article (PubMed ID: 24511107)
1. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. Abrams TA; Meyer G; Schrag D; Meyerhardt JA; Moloney J; Fuchs CS J Natl Cancer Inst; 2014 Feb; 106(2):djt371. PubMed ID: 24511107 [TBL] [Abstract][Full Text] [Related]
2. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer. Lee JJ; Chu E Clin Colorectal Cancer; 2014 Sep; 13(3):135-44. PubMed ID: 24768040 [TBL] [Abstract][Full Text] [Related]
3. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis. Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566 [TBL] [Abstract][Full Text] [Related]
4. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292 [TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810 [TBL] [Abstract][Full Text] [Related]
6. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. Eng C Oncologist; 2010; 15(1):73-84. PubMed ID: 20067946 [TBL] [Abstract][Full Text] [Related]
7. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. Tol J; Koopman M; Cats A; Rodenburg CJ; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; van Groeningen CJ; Sinnige HA; Richel DJ; Voest EE; Dijkstra JR; Vink-Börger ME; Antonini NF; Mol L; van Krieken JH; Dalesio O; Punt CJ N Engl J Med; 2009 Feb; 360(6):563-72. PubMed ID: 19196673 [TBL] [Abstract][Full Text] [Related]
8. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. García-Foncillas J; Díaz-Rubio E Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651 [TBL] [Abstract][Full Text] [Related]
9. Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices. Landsman-Blumberg PB; Carter GC; Johnson BH; Sedgley R; Nicol SJ; Li L; Shankaran V Clin Colorectal Cancer; 2014 Sep; 13(3):178-84. PubMed ID: 25065655 [TBL] [Abstract][Full Text] [Related]
10. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS. Hong YS; Kim HJ; Park SJ; Kim KP; Lee JL; Park JH; Kim JH; Lim SB; Yu CS; Kim JC; Baek JY; Kim SY; Kim TW Cancer Sci; 2013 Apr; 104(4):473-80. PubMed ID: 23298313 [TBL] [Abstract][Full Text] [Related]
11. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Seymour MT; Brown SR; Middleton G; Maughan T; Richman S; Gwyther S; Lowe C; Seligmann JF; Wadsley J; Maisey N; Chau I; Hill M; Dawson L; Falk S; O'Callaghan A; Benstead K; Chambers P; Oliver A; Marshall H; Napp V; Quirke P Lancet Oncol; 2013 Jul; 14(8):749-59. PubMed ID: 23725851 [TBL] [Abstract][Full Text] [Related]
12. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer. Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297 [TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747 [TBL] [Abstract][Full Text] [Related]
14. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Stintzing S; Fischer von Weikersthal L; Decker T; Vehling-Kaiser U; Jäger E; Heintges T; Stoll C; Giessen C; Modest DP; Neumann J; Jung A; Kirchner T; Scheithauer W; Heinemann V Ann Oncol; 2012 Jul; 23(7):1693-9. PubMed ID: 22219013 [TBL] [Abstract][Full Text] [Related]
15. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090 [TBL] [Abstract][Full Text] [Related]
16. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038 [TBL] [Abstract][Full Text] [Related]
17. No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis. Zhou SW; Huang YY; Wei Y; Jiang ZM; Zhang YD; Yang Q; Xie DR PLoS One; 2012; 7(11):e50925. PubMed ID: 23226426 [TBL] [Abstract][Full Text] [Related]
18. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. Kirstein MM; Lange A; Prenzler A; Manns MP; Kubicka S; Vogel A Oncologist; 2014 Nov; 19(11):1156-68. PubMed ID: 25326159 [TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Tol J; Punt CJ Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983 [TBL] [Abstract][Full Text] [Related]
20. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]